Notably, conditional knockout of VEGFR2 in CD8+ T cells could downregulate TOX and reactivate tumor-specific CD8+ T cells, indicating the potential of VEGF/VEGFR2 axis-targeted therapy in rejuvenating exhausted T cells24. This evidence concerns the gene KDR and neoplasm.